MediCure

Since 1987

Innovative Medicine For a Healthier Future

For over 37 years, MediCure Pharmaceuticals has been
dedicated to advancing human health through innovation.

About Us Our Business
Scroll
0Yrs+ Experience
0+ Products
0+ Employees
MediCure R&D Center
37 Years of
Excellence
About MediCure

Relentless Pursuit of
A Healthier Tomorrow

Since its founding in 1987, MediCure Pharmaceuticals has been a comprehensive pharmaceutical company dedicated to researching, developing, and manufacturing high-quality medicines for public health.

With world-class GMP facilities and state-of-the-art research centers, we play a leading role in developing next-generation medicines including anti-cancer drugs, immunotherapies, and biosimilars.

Advanced R&D

400+ research scientists

Global Reach

Exports to 30+ countries

Learn More
Business Area

Core Business Areas

MediCure's key business areas dedicated to human health

01

Prescription Drugs

We hold over 150 prescription drug products across oncology, cardiovascular, and CNS therapeutic areas, continuously expanding our new drug pipeline through sustained R&D efforts.

Learn More
02

Biopharmaceuticals

Focused on next-generation biosimilars and innovative biologics, we are building global competitiveness in the cell and gene therapy sector.

Learn More
03

OTC Products

We manufacture and sell OTC medicines including cold remedies, digestive aids, and pain relievers, and operate the household brand 'CurePlus'.

Learn More
04

CMO Services

Our globally GMP-certified facilities provide contract manufacturing services for various dosage forms including injectables, solid dosage, and semi-solid formulations.

Learn More
Research & Development

Opening the Future
Through R&D Innovation

The MediCure Research Institute, located at our Pangyo R&D Center, employs over 400 researchers with master's and doctoral degrees dedicated to new drug development.

0B KRW Annual R&D Investment
0 Patents Registered Patents
0 Active Clinical Trials

Drug Discovery

AI-powered drug screening

Preclinical

Lead optimization & evaluation

Clinical Trials

Global multi-center trials

Approval & Launch

FDA / EMA / MFDS

Pipeline

R&D Pipeline

Overview of our key new drug development pipeline

Product Indication Category Development Stage
Discovery Preclinical Phase I Phase II Phase III
MC-101 Non-Small Cell Lung Cancer Oncology
MC-205 Rheumatoid Arthritis Immunology
MC-310 Alzheimer's Disease Neurology
MC-422 Diabetic Retinopathy Biologics
MC-518 NASH Metabolic
News & Notice

Latest News

View All
뉴스 Press Release
Jan 28, 2026

MediCure Announces Positive Interim Results of Global Phase III Trial for Alzheimer's Drug MC-310

MediCure Pharmaceuticals' Alzheimer's treatment MC-310 has shown positive interim analysis results in its global Phase III clinical trial...

Jan 15, 2026 Careers

2026 H1 Open Recruitment for New & Experienced Professionals

We are looking for talented individuals to shape the future of MediCure. Positions in R&D, manufacturing, and sales...

Jan 10, 2026 Press Release

MOU Signed with Daiichi Sankyo for Joint Biosimilar Development

MediCure Pharmaceuticals and Japan's Daiichi Sankyo have signed a co-development agreement for three next-generation biosimilars...

Dec 22, 2025 IR

Q4 2025 Earnings Report - Annual Revenue Surpasses KRW 1.2 Trillion

MediCure Pharmaceuticals recorded annual revenue of KRW 1.235 trillion in 2025, achieving its highest-ever performance...

Building a
Healthier Future Together

Join MediCure Pharmaceuticals in creating a healthier tomorrow for humanity.

Contact Us About Us
Contact Us

Get in Touch

Headquarters

521, Teheran-ro, Gangnam-gu
Seoul, Korea 06159

R&D Center

289, Pangyo-ro, Bundang-gu
Seongnam, Gyeonggi, Korea

Manufacturing Plant

123, Osong Saengmyeong-ro
Cheongju, Chungbuk, Korea

General Inquiries

+82-2-1234-5678
contact@medicure.co.kr